WuXi Biologics (Cayman) Inc., an open-access biologics technology platform company, provides solutions to organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing in the People’s Republic of China, North America, Europe, and internationally.
WuXi Biologics (Cayman) Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$117.80|
|52 Week High||HK$59.07|
|52 Week Low||HK$148.00|
|1 Month Change||0.77%|
|3 Month Change||-17.22%|
|1 Year Change||99.32%|
|3 Year Change||346.49%|
|5 Year Change||n/a|
|Change since IPO||1,150.97%|
Recent News & Updates
|2269||HK Life Sciences||HK Market|
Return vs Industry: 2269 matched the Hong Kong Life Sciences industry which returned 99.1% over the past year.
Return vs Market: 2269 exceeded the Hong Kong Market which returned 9.1% over the past year.
Stable Share Price: 2269 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: 2269's weekly volatility (9%) has been stable over the past year.
About the Company
WuXi Biologics (Cayman) Inc., an open-access biologics technology platform company, provides solutions to organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing in the People’s Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sales of medicals; vaccine CDMO and related business; and material supplier activities. It has strategic partnerships with Almirall, S.A.; Vir Biotechnology, Inc.; Aravive, Inc.; Tubulis GmbH; Arcus Biosciences, Inc.; AC Immune SA; and AB2 Bio Ltd.
WuXi Biologics (Cayman) Fundamentals Summary
|2269 fundamental statistics|
Is 2269 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|2269 income statement (TTM)|
|Cost of Revenue||CN¥4.04b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.66|
|Net Profit Margin||34.61%|
How did 2269 perform over the long term?See historical performance and comparison
Is WuXi Biologics (Cayman) undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 2269 (HK$117.8) is trading above our estimate of fair value (HK$108.27)
Significantly Below Fair Value: 2269 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 2269 is poor value based on its PE Ratio (148.4x) compared to the Hong Kong Life Sciences industry average (45.5x).
PE vs Market: 2269 is poor value based on its PE Ratio (148.4x) compared to the Hong Kong market (9.6x).
Price to Earnings Growth Ratio
PEG Ratio: 2269 is poor value based on its PEG Ratio (5.1x)
Price to Book Ratio
PB vs Industry: 2269 is overvalued based on its PB Ratio (12.5x) compared to the HK Life Sciences industry average (6.6x).
How is WuXi Biologics (Cayman) forecast to perform in the next 1 to 3 years based on estimates from 26 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2269's forecast earnings growth (29.3% per year) is above the savings rate (1.5%).
Earnings vs Market: 2269's earnings (29.3% per year) are forecast to grow faster than the Hong Kong market (17.1% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 2269's revenue (32.7% per year) is forecast to grow faster than the Hong Kong market (12.3% per year).
High Growth Revenue: 2269's revenue (32.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2269's Return on Equity is forecast to be low in 3 years time (16.7%).
How has WuXi Biologics (Cayman) performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 2269 has a high level of non-cash earnings.
Growing Profit Margin: 2269's current net profit margins (34.6%) are higher than last year (30.1%).
Past Earnings Growth Analysis
Earnings Trend: 2269's earnings have grown significantly by 54.5% per year over the past 5 years.
Accelerating Growth: 2269's earnings growth over the past year (115%) exceeds its 5-year average (54.5% per year).
Earnings vs Industry: 2269 earnings growth over the past year (115%) exceeded the Life Sciences industry 57.3%.
Return on Equity
High ROE: 2269's Return on Equity (8.5%) is considered low.
How is WuXi Biologics (Cayman)'s financial position?
Financial Position Analysis
Short Term Liabilities: 2269's short term assets (CN¥22.0B) exceed its short term liabilities (CN¥5.4B).
Long Term Liabilities: 2269's short term assets (CN¥22.0B) exceed its long term liabilities (CN¥4.6B).
Debt to Equity History and Analysis
Debt Level: 2269's debt to equity ratio (9.6%) is considered satisfactory.
Reducing Debt: 2269's debt to equity ratio has reduced from 384.6% to 9.6% over the past 5 years.
Debt Coverage: 2269's debt is well covered by operating cash flow (69.5%).
Interest Coverage: 2269 earns more interest than it pays, so coverage of interest payments is not a concern.
What is WuXi Biologics (Cayman) current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 2269's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 2269's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 2269's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 2269's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 2269's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Chris Chen (48 yo)
Dr. Zhisheng Chen, also known as Chris, has been the Chief Executive Officer & Executive Director at WuXi Biologics (Cayman) Inc. since January 01, 2016 and since February 27, 2014 respectively. Dr. Chen i...
CEO Compensation Analysis
Compensation vs Market: Chris's total compensation ($USD4.85M) is above average for companies of similar size in the Hong Kong market ($USD1,000.00K).
Compensation vs Earnings: Chris's compensation has increased by more than 20% in the past year.
Experienced Management: 2269's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Experienced Board: 2269's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.1%.
WuXi Biologics (Cayman) Inc.'s employee growth, exchange listings and data sources
- Name: WuXi Biologics (Cayman) Inc.
- Ticker: 2269
- Exchange: SEHK
- Founded: 2014
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$499.483b
- Shares outstanding: 4.24b
- Website: https://www.wuxibiologics.com
Number of Employees
- WuXi Biologics (Cayman) Inc.
- No. 108, Meiliang Road
- Jiangsu Province
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/25 10:03|
|End of Day Share Price||2021/09/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.